Xilio Therapeutics announces updated Phase 2 data for vilastobart

Xilio Therapeutics (XLO) announced updated data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with metastatic MSS CRC. The data will be presented in a poster session at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. Results include: 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases; Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms; MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C remains on treatment after more than 14 months; combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events